News

Investor's Business Daily on MSN30m
Dow Jones Tumbles, Palantir Hit As Treasury Yields Spike; Snowflake Jumps Late With Tesla Killer Due
Stocks sold off Wednesday as Treasury yields soared. Nvidia, Palantir were losers. Still constructive? Snowflake led earnings ...
Stock Market Today: Dow Falls More Than 800 Points; Bonds Extend Selloff
Trump’s tariffs and the global trade war continue to impact global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.
Stock Market Today: Dow Falls 800 Points; Treasury Yields Rise, Extending Bond Selloff
Trump’s tariffs and the global trade war continue to impact global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.
Investor's Business Daily on MSN5h
Stock Market Today: Dow Jones Crashes 800 Points As Yields Spike And Trump Bill Goes To Vote; Google Charges Higher As Bitcoin Soars (Live Coverage)
Dow stocks fell 800 points as yields rose in trading Wednesday. Nvidia edged higher while Tesla rose ahead of a robotaxi launch in June.
Stock market sinks after Target reports sales drop
Stocks slipped Wednesday amid signs that tariffs are weighing on consumer spending and investor concerns about the U.S. fiscal outlook.
U.S. budget deficits are reaching the tipping point where they could start hurting stocks
Wide U.S. budget deficits have become a fact of life in the U.S., and increasingly, a crucial source of support for stocks. But one former Federal Reserve trader is concerned that this longtime ...
Explore more
Fair Isaac Stock Is Today’s Worst Performer in the S&P 500. Here’s Why.
FICO stock fell 16% to $1,708.55, and was on pace for its largest same-day percentage decrease since a 14% drop in March 2020 ...
Stocks fall, Dow down 800 points as bonds tank amid tax debate. Bitcoin hits fresh high.
US stocks open lower. Target cuts sales outlook but Lowe's tops estimates. 30-year bond yield hits 5% and oil prices rise.
Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue
Shares of Sarepta Therapeutics advanced after the company said it has received the go-ahead from U.K. regulators to keep dosing in a study of its Elevidys treatment for Duchenne muscular dystrophy.